Why use it

Accurate plasma volume estimation is essential for TPE prescription — under-exchanging fails to sufficiently reduce pathological substance levels, while over-exchanging wastes replacement fluid and increases complication risk. This calculator enables precise pre-procedure planning for apheresis teams, allows estimation of substance reduction per session, and supports dosing decisions for multi-session courses. It also calculates cumulative substance removal across planned sessions to guide clinical monitoring.

About

Therapeutic plasma exchange (TPE), also called plasmapheresis, is an extracorporeal treatment in which the patient's plasma is separated from blood cells, removed, and replaced with a substitution fluid — most commonly 5% albumin, fresh frozen plasma (FFP), or a combination. The plasma volume calculator determines the volume of plasma to be processed per session and estimates the fraction of any pathological substance (autoantibody, paraprotein, toxin, ADAMTS13 inhibitor) remaining after each exchange. The plasma volume is estimated using the patient's body weight, sex, and hematocrit. The fractional removal follows first-order kinetics: after exchanging one plasma volume, approximately 63% of the substance is removed (37% remains); after 1.5 volumes, 78% removed (22% remains). The American Society for Apheresis (ASFA) guidelines classify indications into four categories (I–IV) based on strength of evidence, with TPE being Category I for conditions such as TTP, Goodpasture syndrome, myasthenia gravis crisis, and Guillain-Barré syndrome. The standard protocol for most conditions is 1.0–1.5 plasma volumes per session, performed daily or every other day for 5–7 sessions, with response reassessment after the initial course.

When to use

Pre-procedure planning for any therapeutic plasma exchange prescription
Estimating fractional removal of pathological substance (autoantibody, inhibitor, cryoglobulin, paraprotein) per session
Calculating total exchange volume for nursing and apheresis machine programming
Planning multi-session courses — estimating cumulative substance levels after each session
Conditions with ASFA Category I or II indications: TTP, anti-GBM disease, myasthenia gravis crisis, Guillain-Barré syndrome, ANCA vasculitis with DAH, NMDA-receptor encephalitis, familial hypercholesterolemia
NOT a substitute for ASFA guideline review for indication category and optimal replacement fluid selection
NOT applicable to LDL apheresis (different technique and calculation)

Formula

PLASMA VOLUME ESTIMATION: Total Blood Volume (TBV): Male: TBV = weight (kg) × 70 mL/kg Female: TBV = weight (kg) × 65 mL/kg Plasma Volume (PV) = TBV × (1 − Hct/100) Nadler Equation (more precise): Male: TBV = 0.3669 × H³(m) + 0.03219 × W(kg) + 0.6041 (L) Female: TBV = 0.3561 × H³(m) + 0.03308 × W(kg) + 0.1833 (L) EXCHANGE VOLUME: Volume per session = N × PV where N = number of plasma volumes prescribed (typically 1.0–1.5) FRACTION REMAINING AFTER EXCHANGE: Fraction remaining = e^(−N) Percent removed = (1 − e^(−N)) × 100% N = 1.0 PV: ~63% removed, 37% remains N = 1.25 PV: ~71% removed, 29% remains N = 1.5 PV: ~78% removed, 22% remains N = 2.0 PV: ~86% removed, 14% remains

Pearls & pitfalls

Plasma volume estimation using weight and hematocrit (PV = TBV × [1 − Hct]) is accurate to within ~5–10% in normovolemic patients. Nadler equation (incorporating height) improves precision, especially in very tall or obese patients.
After ONE plasma volume exchange: approximately 63% of the substance is removed, 37% remains. After 1.5 volumes: 78% removed, 22% remains. After TWO volumes: 86% removed, 14% remains — the incremental benefit diminishes significantly beyond 1.5 volumes.
Standard prescription: 1.0–1.5 plasma volumes per session. Exchanging >1.5 plasma volumes provides modest additional removal at the cost of substantially more replacement fluid — rarely justified except for highly refractory cases.
For TTP: FFP is the MANDATORY replacement fluid to replenish ADAMTS13. Cryoprecipitate-poor FFP or solvent-detergent FFP reduce allergic reactions and infection transmission risk. Albumin is CONTRAINDICATED as the sole replacement in TTP.
For anti-GBM disease (Goodpasture): combine TPE with immunosuppression (cyclophosphamide + prednisone). Circulating anti-GBM antibody levels should be monitored to determine treatment duration — continue until antibodies are undetectable.
Hypocalcemia is the most common acute complication of TPE — citrate in replacement FFP chelates ionized calcium. Prophylactic oral calcium supplementation (500 mg calcium carbonate before each session) or IV calcium gluconate infusion during exchange reduces this risk.
Immunoglobulin depletion occurs with TPE — IgG falls to ~30% of baseline after one plasma volume exchange. Patients on chronic TPE are at increased infection risk and may require prophylactic antibiotics or IVIG supplementation.
The inter-session rebound of pathological substances depends on the substance half-life and production rate. Autoantibodies (IgG t½ ~21 days) rebound slowly; ADAMTS13 inhibitors in TTP rebound rapidly — the treatment schedule must account for this.
Exchange volume should be based on IDEAL plasma volume, not actual — obese patients have a higher proportion of fat mass (low water content), so weight-based TBV formulas overestimate plasma volume. Use lean body weight or the Nadler equation for accuracy in obesity.

Next steps

After calculating plasma volume and exchange volume per session: confirm replacement fluid selection per ASFA guidelines (5% albumin for most conditions; FFP mandatory for TTP — replaces deficient ADAMTS13); programme the apheresis machine with the calculated exchange volume; plan vascular access (large-bore peripheral IV adequate for short courses; tunneled catheter for extended courses); monitor CBC, coagulation studies (PT, fibrinogen), calcium, and immunoglobulin levels during the exchange course; reassess clinical response after 3–5 sessions and adjust the schedule accordingly.

Evidence

Kaplan AA, Halley SE. Plasma exchange with a rotating filter. Kidney Int. 1990;38(1):160-166. Schwartz J et al. Guidelines on the use of therapeutic apheresis in clinical practice — evidence-based approach from the Writing Committee of the American Society for Apheresis: 8th Special Issue. J Clin Apher. 2023;38(2):77-278. PMID:36924653. Plasma volume formula: Nadler SB, Hidalgo JU, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962;51(2):224-232.

References

Schwartz J et al. Guidelines on the use of therapeutic apheresis in clinical practice (8th Special Issue). J Clin Apher. 2023;38(2):77-278. — link
Nadler SB, Hidalgo JU, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962;51(2):224-232. — link
Kaplan AA. A practical guide to therapeutic plasma exchange. Blackwell Science; 1999. — link
Winters JL. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. Hematology Am Soc Hematol Educ Program. 2012;2012:7-12. — link

Therapeutic Plasmapheresis Calculator

Calculator